Related Experiment Video
Updated: Jun 17, 2026
09:12
Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
Published on: April 5, 2024
Adeno-associated viral vector purification using a centrifugal microfluidic system: towards workflow automation for
Matthias Geissler1,2, Lidija Malic1,2, Liviu Clime1,2
1Medical Devices Research Centre, National Research Council of Canada, 75 de Mortagne Boulevard, Boucherville, QC, J4B 6Y4, Canada. matthias.geissler@cnrc-nrc.gc.ca.
Lab on a Chip
|June 16, 2026
Summary
This study presents a novel microfluidic assay for rapid adeno-associated virus (AAV) purification. The automated system efficiently isolates AAV particles from crude lysate in under an hour, improving gene therapy manufacturing.
Area of Science:
- Biotechnology
- Bioengineering
- Molecular Biology
Background:
- Adeno-associated virus (AAV) is a critical vector for gene therapy.
- Current AAV purification methods can be time-consuming and labor-intensive.
- Scalable and efficient purification is essential for AAV manufacturing.
Purpose of the Study:
- To develop an integrated, automated microfluidic assay for AAV particle purification.
- To optimize the process for speed, efficiency, and compatibility with low-volume samples.
- To validate the purification performance, including DNA removal and biological activity.
Main Methods:
- Development of a microfluidic cartridge with POROS™ CaptureSelect™ AAVX Affinity Resin.
- Utilized a centrifugal platform for pneumatic liquid actuation.
- Integrated 22 automated steps for purification from crude lysate to conditioned AAV sample.
- Numerical simulations for flow uniformity and experimental validation with AAV8.
Main Results:
- Achieved AAV purification in approximately 30-60 minutes.
- Demonstrated higher extraction efficiency compared to manual spin column methods.
- Validated plasmid DNA removal exceeding 99.99% via qPCR.
- Confirmed biological activity of purified AAV particles in transduction assays.
Conclusions:
- The integrated microfluidic assay offers a rapid and efficient method for AAV purification.
- The platform addresses limitations in current gene therapy manufacturing, particularly for low-volume production.
- This technology has the potential to streamline quality control and accelerate AAV production.
